文献速递心境障碍精神分裂症与精神病性障碍

双相障碍、精神分裂症与重性抑郁障碍的遗传易感性分化及双相障碍表型异质性

Genetic Liabilities Differentiating Bipolar Disorder, Schizophrenia, and Major Depressive Disorder, and Phenotypic Heterogeneity in Bipolar Disorder.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

该研究利用英国双相障碍研究网络数据,通过基因组结构方程模型识别双相障碍、精神分裂症和重性抑郁障碍共享及分化的遗传易感性成分,并在独立双相障碍样本中检验多基因风险评分与症状的关联。结果显示躁狂、精神病性症状和抑郁分别与分化双相障碍、精神分裂症和重性抑郁障碍的遗传成分相关。

要点

  • 双相障碍的躁狂症状与共享遗传成分及分化双相障碍的遗传成分相关。
  • 精神病性症状与共享遗传成分及分化精神分裂症的遗传成分相关。
  • 抑郁症状与较高的重性抑郁障碍分化成分和较低的双相障碍分化成分相关。

核心结论

  • 双相障碍的临床异质性反映了双相障碍易感性负荷及对其他障碍风险有分化效应的等位基因贡献。
  • 躁狂、精神病性症状和抑郁分别与分化双相障碍、重性抑郁障碍和精神分裂症的遗传易感性成分相关。

研究设计与样本

  • 研究使用英国双相障碍研究网络数据,对精神分裂症、双相障碍和重性抑郁障碍的全基因组关联研究应用基因组结构方程模型识别易感性成分。
  • 纳入符合DSM-IV双相障碍I型或II型或分裂情感性障碍双相型的成人,数据收集于2000年1月至2013年12月,分析于2020年6月至2022年2月。
  • 在独立双相障碍数据集中检验代表各成分的多基因风险评分与双相情感障碍维度量表测量的症状的关联。

主要发现

  • 共纳入4429名参与者,其中3012名(68.0%)为女性,平均(SD)年龄46.2(12.3)岁。
  • 躁狂与共享易感性成分相关(β=0.29;95%CI,0.23-0.34;P=3.04×10^-25),精神病性与共享成分相关(β=0.05;95%CI,0.04-0.07;P=2.33×10^-13)。
  • 躁狂与分化精神分裂症的成分相关(β=0.08;95%CI,0.03-0.14;P=.002),精神病性与该成分相关(β=0.03;95%CI,0.01-0.04;P=1.0×10^-4)。
  • 躁狂与分化双相障碍的成分相关(β=0.14;95%CI,0.09-0.20;P=1.99×10^-7),精神病性与该成分相关(β=0.02;95%CI,0.01-0.03;P=.006)。
  • 抑郁与较高的重性抑郁障碍分化成分相关(β=0.07;95%CI,0.01-0.12;P=.01),与较低的双相障碍分化成分相关(β=-0.11;95%CI,-0.17至-0.06;P=7.06×10^-5)。

关键数值与推荐

  • 分化双相障碍的成分独立于精神病性效应与躁狂相关(β=0.14;95%CI,0.08-0.20;P=4.32×10^-6),但与精神病性无独立于躁狂的关联。
  • 分化精神分裂症的成分独立于躁狂效应与精神病性相关(β=0.01;95%CI,0.003-0.03;P=.02),但与躁狂无独立于精神病性的关联。
  • 精神病性症状的心境不一致仅与分化精神分裂症的成分相关(β=0.03;95%CI,0.01-0.05;P=.005)。

临床怎么用

  • 理解病因异质性有助于识别双相障碍不同的病理生理过程、对患者进行分层并开发精准治疗。
  • 遗传易感性成分可能为双相障碍症状维度的评估和个体化干预提供参考。

局限性

  • 研究基于欧洲 ancestry 样本,结果推广至其他人群需谨慎。
  • 多基因风险评分仅解释部分遗传变异,环境因素未纳入分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Understanding the origins of clinical heterogeneity in bipolar disorder (BD) will inform new approaches to stratification and studies of underlying mechanisms. OBJECTIVE: To identify components of genetic liability that are shared between BD, schizophrenia, and major depressive disorder (MDD) and those that differentiate each disorder from the others and to examine associations between heterogeneity for key BD symptoms and each component. DESIGN, SETTING, AND PARTICIPANTS: Using data from the Bipolar Disorder Research Network in the United Kingdom, components of liability were identified by applying genomic structural equation modeling to genome-wide association studies of schizophrenia, BD, and MDD. Polygenic risk scores (PRS) representing each component were tested for association with symptoms in an independent BD data set. Adults with DSM-IV BD or schizoaffective disorder, bipolar type, were included. Data were collected from January 2000 to December 2013, and data were analyzed from June 2020 to February 2022. MAIN OUTCOMES AND MEASURES: PRS representing the components of liability were tested for association with mania and depression, psychosis, and mood incongruence of psychosis in participants with BD, measured using the Bipolar Affective Disorder Dimensional Scale. RESULTS: Of 4429 included participants, 3012 (68.0%) were female, and the mean (SD) age was 46.2 (12.3) years. Mania and psychosis were associated with the shared liability component (mania β = 0.29; 95% CI, 0.23-0.34; P = 3.04 × 10-25; psychosis β = 0.05; 95% CI, 0.04-0.07; P = 2.33 × 10-13) and the components that differentiate each of schizophrenia (mania β = 0.08; 95% CI, 0.03-0.14; P = .002; psychosis β = 0.03; 95% CI, 0.01-0.04; P = 1.0 × 10-4) and BD (mania β = 0.14; 95% CI, 0.09-0.20; P = 1.99 × 10-7; psychosis β = 0.02; 95% CI, 0.01-0.03; P = .006) from the other disorders. The BD differentiating component was associated with mania independently of effects on psychosis (β = 0.14; 95% CI, 0.08-0.20; P = 4.32 × 10-6) but not with psychosis independently of mania. Conversely, the schizophrenia differentiating component was associated with psychosis independently of effects on mania (β = 0.01; 95% CI, 0.003-0.03; P = .02), but not with mania independently of psychosis. Mood incongruence of psychosis was associated only with the schizophrenia differentiating component (β = 0.03; 95% CI, 0.01-0.05; P = .005). Depression was associated with higher MDD differentiating component (β = 0.07; 95% CI, 0.01-0.12; P = .01) but lower BD differentiating component (β = -0.11; 95% CI, -0.17 to -0.06; P = 7.06 × 10-5). CONCLUSIONS AND RELEVANCE: In this study of BD, clinical heterogeneity reflected the burden of liability to BD and the contribution of alleles that have differentiating effects on risk for other disorders; mania, psychosis, and depression were associated with the components of genetic liability differentiating BD, MDD, and schizophrenia, respectively. Understanding the basis of this etiological heterogeneity will be critical for identifying the different pathophysiological processes underlying BD, stratifying patients, and developing precision therapeutics.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Richards AL, Cardno A, Harold G, et al. Genetic Liabilities Differentiating Bipolar Disorder, Schizophrenia, and Major Depressive Disorder, and Phenotypic Heterogeneity in Bipolar Disorder. JAMA Psychiatry. 2022. PMID: 36044200. doi:10.1001/jamapsychiatry.2022.2594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。